Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance

Controlled Clinical Trials

Volumn 18, Issue 6, 1997, Pages 557-560

  Davis, C E ^a  

^a IL   (United States)

Author keywords

Clinical trials; Endpoints; Secondary endpoints

Indexed keywords

ACETYLSALICYLIC ACID; ENALAPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; HEART INFARCTION; HUMAN; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CLINICAL TRIALS; CORONARY DISEASE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0030670880     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(96)00133-X     Document Type: Conference Paper

References (6)

1. Pocock SJ. Clinical Trials. New York: John Wiley and Sons, Inc.; 1983.
2. Friedman LM, Furberg CD, MeMets DL. Fundamentals of Clinical Trials, 3rd ed. St. Louis: Mosby Year Book, Inc.
3. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD): rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990;66:315-322.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
6. Findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988;318:262-264. Preliminary report.